Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Liabilities and Shareholders Equity (2024 - 2025)

Prelude Therapeutics' Liabilities and Shareholders Equity history spans 2 years, with the latest figure at $141.3 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 19.49% year-over-year to $141.3 million; the TTM value through Dec 2025 reached $492.2 million, down 41.69%, while the annual FY2025 figure was $141.3 million, 19.49% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $141.3 million at Prelude Therapeutics, up from $94.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $247.1 million in Q1 2024 and bottomed at $94.8 million in Q3 2025.